NorthWest Biotherapeutics Inc (NWBO)

[Gus1212]

Roche RHHBY announced that the FDA has granted Breakthrough Therapy Designation (BTD) to tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT in combination with its immuno-oncology drug, Tecentriq (atezolizumab).

The combination has been granted the designation for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations.